Amgen To Present Four Cardiovascular Research Abstracts

Amgen (AMGN) said Tuesday that it will present four cardiovascular research abstracts, including final data from the Repatha or evolocumab open label extension trial of patients living with HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular events, including complex revascularization procedures.

The company will present additional abstracts, including a simulation comparing the impact of different LDL-C guidelines on CV risk reduction, as well as negative control outcomes to assess residual bias when comparing PCSK9 inhibitors to other treatments.

The company noted that it will present those analyses at the American College of Cardiology's 70th Annual Scientific Session & Expo (ACC.21), May 15-17, 2021.

According to Amgen, the data in HIV confirm the safety and efficacy of Repatha across different patient populations and contribute to Amgen's PROFICIO program of clinical and real-world evidence studies investigating the impact of Repatha on cardiovascular disease.

Amgen recently passed the milestone of more than one million patients receiving Repatha worldwide.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
Follow RTT